Company news
Exicure, Inc. news in 2025
Exicure, Inc.'s news releases, calls and decks from 2025, newest first.
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
December 8, 2025
Exicure, Inc. Reports Third Quarter 2025 Financial Results
November 7, 2025
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
November 3, 2025
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
October 6, 2025
Exicure, Inc. Reports Second Quarter 2025 Financial Results
August 8, 2025
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
August 4, 2025
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
August 1, 2025
Exicure, Inc. Reports First Quarter 2025 Financial Results
June 27, 2025
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
May 28, 2025
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
May 5, 2025
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
April 14, 2025
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
April 11, 2025
Exicure, Inc. Reports Full Year 2024 Financial Results
March 18, 2025
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
March 13, 2025
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
January 21, 2025